On June 14, Ambrx and Zhejiang Pharmaceuticals announced in San Diego and Shanghai that they have reached an agreement to develop monoclonal antibody drug conjugates (ADCs) for the treatment of breast cancer.
From July 9th to 15th, Dr. Xu Xinde from Xinchang Pharmaceutical Factory was invited to participate in the "Macular Carotenoids 2013" International Academic Conference held at the University of Cambridge, England. At the meeting, the toxicological study of meso-zeaxanthin was made. Special Report.
